

## 2020 YEAR - IN - REVIEW

## ■ NEW CLIENTS, MORE SAVINGS ■

529 new clients

in 2020

43%

of clients had **lower PMPM drug spend** than

prior to implementing

the Reformulary **PMPM** = Per Member Per Month

1.5%



PMPY\* drug spend for Reformulary clients grew at 1.5% CAGR between 2015 and 2020. **Compared to 3.28% industry average**.

\*Weighted average Per Member Per Year (PMPY)



Our clients would have spent **9.4% more**\* if they had not implemented the Reformulary

<sup>+</sup>Present value (PV) of savings between 2015 and 2020 30.5%

Inflation in specialty drug spend: 1.6% for Reformulary clients compared to 30.5% for private plans\*\*

\*\*Weighted average from block of private plans comprising ~2.5 million claimants

#### WE PUT IN THE TIME -

64

new pipeline drugs reviewed



**71 detailed drug reviews** for new Health Canada-approved drugs



major drug class reviews completed



Expert-informed criteria for 53 new specialty drugs

9,914

DINs reviewed and verified in rebuilding the drug price file within our master analytics database



clinical publications reviewed for Cannabis Standard formulary

## ADDED VALUE ---



Launched Cannabis
Standard Index, creating
searchable web platform
of 160 unique cannabis
products, categorized
according to
36 different fields



**Launched Quality of Life** survey
tool & developed **Productivity tool**for Canadians

# ■ TOGETHER, WE WENT VIRTUAL ■



virtual meetings hosted by our CEO, replacing in-person meetings

# my Request\*\*

Launched myRequest Services for plan members



Connecting our vast data assets using data fabric technology by Cinchy

### GIVING IT OUR BEST -



Signed pledge to join the **BlackNorth Initiative** 

#### **EVERYDAY HEROES**



Thanks to our frontline workers nurses, doctors, pharmacists, truck drivers, transit operators, grocery store staff, among many others

